Asston Pharmaceuticals Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,060,000 (47%) | — | ₹1,304 Cr |
| NII (HNI) | — | 322,000 (14%) | — | ₹396 Cr |
| Retail | — | 746,000 (33%) | — | ₹918 Cr |
| Market Maker | — | 113,000 (5%) | — | ₹14 Cr |
| Σ Total | — | 2,241,000 (100%) | — | ₹27,564 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹123,000 |
| Retail (Max) | 13 | 13,000 | ₹1,599,000 |
| S-HNI (Min) | 14 | 14,000 | ₹1,722,000 |
| B-HNI (Min) | 67 | 67,000 | ₹8,241,000 |
Financial Statements Amount In Crore
| Metric | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 6 | 26 | 16 |
| EBITDA | 2 | 6 | 3 |
| Profit After Tax | 1 | 4 | 1 |
| Net Worth | 12 | 11 | 6 |
| Total Assets | 32 | 28 | 20 |
| Reserves & Surplus | 6 | 4 | 6 |
| Total Borrowing | 8 | 7 | 7 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit – 6.00
- 2 Funding the incremental working capital requirements of the Company – 13.00
- 3 Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company – 1.00
- 4 General Corporate Purposes – 3.95
Company Overview
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
- Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
- Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
- Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
- Ferrovit Syrup: To treat vitamin and mineral deficiencies.
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
- Formulation Expertise
- Experienced Promoters
- Wide range of Products
- Strategic Location
- Skilled Workforce